Infosys $560M Acquisitions Draw Analyst Praise: Nomura Sets Rs 1810 Target
Following Infosys' $560 million strategic acquisitions in healthcare and insurance sectors, Nomura maintains Buy rating with Rs 1810 target price, expecting 225 basis points growth boost in FY27. Morgan Stanley rates Equal Weight at Rs 1760, noting the acquisitions will add 1.2% to FY27 revenue but remain earnings neutral to slightly dilutive.

*this image is generated using AI for illustrative purposes only.
Infosys Board has formally approved two major strategic acquisitions worth up to $560 million during their meeting held on March 25, 2026. The acquisitions target specialized firms in healthcare digital transformation and insurance consulting technology sectors, representing a significant expansion of the company's domain expertise.
Analyst Reactions and Price Targets
Following the acquisition announcement, leading investment firms have updated their outlook on Infosys. Nomura maintains its Buy rating with a target price of Rs 1810.00, expecting the $560 million acquisitions to add approximately 225 basis points to FY27 growth while expanding healthcare and life sciences capabilities and bringing new clients.
| Analyst Ratings: | Details |
|---|---|
| Nomura Rating: | Buy maintained |
| Nomura Target Price: | Rs 1810.00 |
| Expected FY27 Growth Impact: | ~225 basis points |
| Morgan Stanley Rating: | Equal Weight |
| Morgan Stanley Target Price: | Rs 1760.00 |
| Expected Revenue Impact: | ~1.20% of FY27 revenue |
Morgan Stanley rates Infosys as Equal Weight with a target price of Rs 1760.00, noting that while the acquisitions of Optimum Healthcare IT ($465 million) and Stratus (up to $95 million) will add approximately 1.20% to FY27 revenue, they are expected to be neutral to slightly dilutive to earnings.
Board Meeting and Regulatory Approval
The Board meeting, which commenced at 8:35 p.m. IST and concluded at 9:17 p.m. IST on March 25, 2026, approved both acquisition transactions under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
| Meeting Details: | Information |
|---|---|
| Meeting Date: | March 25, 2026 |
| Start Time: | 8:35 p.m. IST |
| End Time: | 9:17 p.m. IST |
| Regulatory Framework: | SEBI Regulation 30 |
Healthcare Digital Transformation Acquisition
The larger acquisition involves Optimum Achieve Holdings, Inc. along with its subsidiaries, including Optimum Healthcare IT, LLC. This Best in KLAS healthcare digital transformation and consulting firm brings 1,600+ experts with deep healthcare provider domain expertise.
| Optimum Healthcare IT Details: | Specifications |
|---|---|
| Acquisition Value: | Up to $465 million |
| Expert Team Size: | 1,600+ professionals |
| Founded: | 2012 |
| Headquarters: | Florida, US |
| Specialization: | Healthcare IT digital transformation |
| Expected Closure: | First quarter of FY 2027 |
Optimum Healthcare IT's revenue performance shows strong growth trajectory with FY25 revenue of $275.90 million, compared to $106.60 million in FY24 and $114.30 million in FY23.
Insurance Technology Expansion
The second acquisition targets Stratus Global LLC, a leading technology solutions provider for the property & casualty (P&C) insurance industry. Stratus brings 450+ experts with specialized Guidewire consulting capabilities.
| Stratus Global LLC Details: | Specifications |
|---|---|
| Acquisition Value: | Up to $95 million |
| Expert Team Size: | 450+ professionals |
| Founded: | 2001 |
| Headquarters: | New Jersey, US |
| Specialization: | P&C insurance, Guidewire solutions |
| Global Presence: | US, Canada, India |
Stratus recorded steady revenue growth with FY25 revenue of $42.80 million, up from $36.20 million in FY24 and $35.10 million in FY23.
Strategic Value and Market Position
Nomura reinforces Infosys as a top large-cap IT pick, highlighting how these acquisitions will enhance the company's capabilities by integrating specialized domain expertise with Infosys Topaz AI offerings and Infosys Cobalt cloud offerings. The healthcare acquisition requires anti-trust approvals under US competition laws, while the insurance acquisition requires no governmental approvals.
| Combined Investment Overview: | Value |
|---|---|
| Healthcare Sector Investment: | Up to $465 million |
| Insurance Sector Investment: | Up to $95 million |
| Total Strategic Investment: | Up to $560 million |
| Expected Completion: | First quarter of FY 2027 |
Both transactions are structured as 100% equity acquisitions through Infosys Nova Holdings LLC, a wholly owned subsidiary of Infosys Limited, with cash consideration including upfront payments and earnouts.
Historical Stock Returns for Infosys
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.73% | +0.21% | -1.58% | -14.49% | -22.03% | -4.81% |
How will Infosys integrate its AI-powered Topaz platform with the newly acquired healthcare and insurance domain expertise to create competitive advantages?
What additional acquisitions might Infosys pursue to further strengthen its healthcare and P&C insurance verticals following these strategic investments?
Will the potential earnings dilution from these acquisitions impact Infosys's ability to maintain its dividend policy and shareholder returns in FY27?


































